The European Parliament completes a landmark vote in favour of the European Commission proposal to introduce a new regulation for plants obtained by certain new genomic techniques (NGTs) and their food and feed.The proposal aims to increase the sustainability and resilience of the EU food system by enabling the development of improved plant varieties that are climate resilient, pest resistant, that require less fertilisers and pesticides, can secure higher yields and reduce the EUs dependency on agricultura ...

The Environment Committee of the European Parliament votes in favour of the European Commission proposal to introduce a new regulation on plants obtained by certain new genomic techniques (NGTs) and their food and feed. The Committee's report indicates that NGTs have the ability to enhance agriculture by making crops more resilient and sustainable whilst providing unprecedented opportunities for European agriculture and food production.The proposed regulation identifies a ‘Conventional-like' category of NGT ...

Cibus continues to confirm tolerance of HT1 and HT3 rice traits to commercial herbicide application rates in field trials and achievement of the Cibus Powered™ standardFollowing another successful season of field evaluation of HT1 and HT3 rice herbicide tolerance traits, Cibus to begin field scale demonstration in the US Mid-South in preparation for product launchCibus canola Pod Shatter Reduction (PSR) trait continues to demonstrate a high level of pod shatter reduction in seed developer genetics and achie ...

Cibus, Inc. (NASDAQ:CBUS) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating Officer Conference Call Participants Bobby Burleson - Canaccord Genuity Kevin Estok - Jefferies Operator Good afternoon, and welcome to the Cibus Third Quarter 2023 Results Conference Call. [Operator Instructions] Please also note, today's event is ...

Business Model and Trait Development - The company's core business model focuses on three crops (canola, rice, soybean) and five traits (PSR, HT1, HT2, HT3, Sclerotinia resistance), which represent a significant business opportunity and economic foundation[107] - Initial transfers of customer elite germplasm have started towards commercialization in the field, indicating strong customer demand for the developed traits in canola and rice[107] - The company positions itself as a leader in gene editing and trait development, aiming to improve efficiency and effectiveness in addressing agriculture's productivity issues[107] - Cibus Global focuses on gene editing technologies to develop plant traits that improve farming productivity and produce low carbon plant products[151] Financial Performance and Metrics - Total assets increased significantly to $796.235 million in September 2023 from $22.421 million in December 2022[137] - Net loss for the three months ended September 30, 2023, was $34.528 million, compared to $5.950 million in the same period in 2022[140] - Comprehensive loss for the nine months ended September 30, 2023, was $60.418 million, compared to $14.054 million in the same period in 2022[140] - Cash and cash equivalents increased to $31.883 million in September 2023 from $3.427 million in December 2022[137] - Goodwill increased to $585.266 million in September 2023 from $0 in December 2022[137] - Total current liabilities increased to $25.079 million in September 2023 from $1.662 million in December 2022[137] - Net cash used by operating activities for the nine months ended September 30, 2023, was $29.193 million, compared to $15.601 million in the same period in 2022[148] - Cash acquired from the merger with Cibus Global, LLC was $59.381 million in the nine months ended September 30, 2023[148] - Total stockholders' equity increased to $463.390 million in September 2023 from $7.233 million in December 2022[137] - Redeemable noncontrolling interest was $129.104 million in September 2023[137] - Revenue for the three months ended September 30, 2023, was $475,000, compared to $42,000 for the same period in 2022[164] - Net loss for the three months ended September 30, 2023, was $34.5 million, compared to $5.95 million for the same period in 2022[164] - Research and development expenses for the three months ended September 30, 2023, were $17.5 million, compared to $3.0 million for the same period in 2022[164] - Selling, general, and administrative expenses for the three months ended September 30, 2023, were $8.75 million, compared to $3.23 million for the same period in 2022[164] - The Company's total operating expenses for the three months ended September 30, 2023, were $26.3 million, compared to $6.2 million for the same period in 2022[164] - Net loss for the nine months ended September 30, 2023 was $60.4 million[183] - Cash used for operating activities was $29.2 million for the nine months ended September 30, 2023[183] - As of September 30, 2023, the company had $31.9 million in cash and cash equivalents and $25.1 million in current liabilities[184] - The company recorded $0.7 million in revenue, $35.5 million in net loss attributable to controlling interest, and $9.9 million in net loss attributable to redeemable noncontrolling interest for the nine months ended September 30, 2023[288] - Pro forma revenues for the nine months ended September 30, 2023, were $1.154 million, compared to $992 million for the same period in 2022[289] Merger and Stock Transactions - The company completed a one-for-ten reverse stock split effective April 24, 2023, and a one-for-five reverse stock split effective May 31, 2023[114][132] - The company completed a merger transaction on May 31, 2023, resulting in an "Up-C" structure with Class A and Class B Common Stock[113] - Cibus, Inc. completed the Merger Transactions with Cibus Global on May 31, 2023, consolidating financial results and reporting redeemable noncontrolling interest[150] - At the closing of the Merger Transactions, the Company issued 16,527,484 shares of Class A Common Stock and 4,642,636 shares of Class B Common Stock to Cibus Global equityholders[152] - Legacy Calyxt stockholders held approximately 4.8% of the issued and outstanding common stock, while legacy Cibus Global holders held approximately 95.2%[152] - The Company effected a one-for-five reverse stock split prior to the Merger Transactions, effective May 31, 2023[154] - The company issued 15,508,202 shares of Class A Common Stock resulting from the merger with Cibus Global, LLC[177] - The company's authorized shares consist of 210,000,000 shares of Class A Common Stock and 90,000,000 shares of Class B Common Stock[181] - As of September 30, 2023, the company had 16,659,996 shares of Class A Common Stock outstanding and 4,642,636 shares of Class B Common Stock outstanding[182] - The company issued 16,527,484 shares of Class A Common Stock and 4,642,636 shares of Class B Common Stock to Cibus Global equityholders as part of the Merger Transactions[304] Liquidity and Capital Resources - The company's primary source of liquidity is its cash and cash equivalents, with additional capital resources accessible from the capital markets[183] - The company anticipates continuing to generate losses for the next several years and expects to finance future cash needs through various means including cash on hand, commercialization activities, and equity or debt financings[202] - Management will need to raise additional capital to support its business plans to continue as a going concern within one year after the date these financial statements are issued[203] - The company received net proceeds of $10.0 million from the Follow-On Offering, after deducting $0.9 million in underwriting discounts and estimated offering expenses[301] Revenue Recognition and Deferred Revenue - The company's revenues represent amounts earned from collaboration agreements related to contract research, recognized under Topic 606 Revenue from Contracts with Customers[194] - Accounts receivable allowance for credit losses was $0 as of September 30, 2023, and December 31, 2022[207] - Deferred revenue recognized as revenue for the three months ended September 30, 2023, was $0.5 million[216] - Deferred revenue recognized as revenue for the nine months ended September 30, 2023, was $0.1 million[216] - The Company's deferred revenue balance as of September 30, 2023, was $1.637 million, up from $107,000 as of December 31, 2022[244] Expenses and Costs - The Company incurred $8.2 million in expenses related to the Merger Transactions, with $3.5 million in legal and professional fees, $1.9 million in severance costs, and $1.1 million in stock compensation expense included in SG&A for the nine months ended September 30, 2023[238] - The Company recognized $0.4 million of deferred financing costs related to Common Warrants in SG&A expense during the second quarter of 2023[245] - The Company's R&D costs include salaries, lab supplies, consultant fees, and allocated facility costs, which are expensed as incurred[218] - The Company's SG&A expense includes costs related to intellectual property portfolio management and patent filing, which were reclassified from R&D to SG&A starting in the second quarter of 2023[217] - The Company recognized $0.2 million related to the Employee Retention Credit (ERC) as of September 30, 2023, with no further credits expected[255] Stock Options and Warrants - The Company's total stock options and unvested equity awards outstanding as of September 30, 2023, were 1,412,013, compared to 323,229 as of September 30, 2022[223] - Weighted average shares of Class A Common Stock outstanding excludes unvested Class A Common Stock, which are treated as issued and outstanding only after vesting[250] - The Company's potential dilutive securities, including Common Warrants and unvested stock units, were excluded from diluted net loss per share calculations due to their anti-dilutive effect[251] - Common Warrants issued in the Follow-On Offering expire on August 23, 2027, and are exercisable for one share of Class A Common Stock at $69.04 per share[252] - The estimated fair value of Common Warrants as of September 30, 2023, was $9.54 million, with an expected volatility of 107.1% and a risk-free interest rate of 4.7%[294] Intangible Assets and Goodwill - The company recognized goodwill totaling $585.3 million from the Merger Transactions with Cibus Global, representing future economic benefits from the acquisition[297] - The company's intangible assets as of September 30, 2023, include $99.051 million in in-process research and development, $14.148 million in developed technology, and $22.230 million in trade name[298] - The Company's definite-lived intangible assets have a weighted average amortization period of 20 years[265] - Total amortization expense for the remainder of 2023 is estimated at $458 thousand, with annual expenses of $1.833 million from 2024 to 2028[279] Tax and Financial Agreements - The Company will pay 85% of net income tax savings to Electing Members under the Tax Receivable Agreement (TRA) related to the Merger Transactions[267] - The fair value of Level 3 liabilities increased from $291 thousand as of December 31, 2022, to $1.512 million as of September 30, 2023[272] Property, Plant, and Equipment - Total property, plant, and equipment increased from $4.516 million as of December 31, 2022, to $17.197 million as of September 30, 2023[276] Other Financial Information - The company's money market funds had a fair value of $7.389 million as of September 30, 2023, classified as Level 1 assets[292] - The company financed its enterprise science platform annual software license at an annual interest rate of 10.9%, with the note maturing in July 2024[299] - Redeemable noncontrolling interest holders owned approximately 22% of Cibus Global as of May 31, 2023, and September 30, 2023[258] - The purchase price for Cibus Global was $634,751,397, calculated based on 20,150,838 shares of Common Stock at a fair value of $31.50 per share[234] Investor Relations and Communication - The company provides email alerts for new press releases posted on its website, allowing investors to stay updated on announcements[136] Industry Risks and Uncertainties - The company's industry is subject to high uncertainty and risk, as outlined in various SEC filings, including Form 8-K and Form 10-Q[135]

Cibus, Inc. (NASDAQ:CBUS) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating Officer Conference Call Participants Laurence Alexander - Jefferies Steve Byrne - Bank of America Bobby Burleson - Canaccord Genuity Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Cibus Second Quarter 2023 Fin ...

All of the issued and outstanding Cibus Global membership units (Common Units) are held solely by the Company and certain members of Cibus Global who elected in connection with the Merger Transactions to receive units (Up-C Units) consisting of one share of Class B Common Stock and one Common Unit at the closing of the Merger Transactions (Electing Members). The Up-C Units are generally exchangeable for shares of Class A Common Stock on a one-for-one basis, subject to certain restrictions. In accordance wit ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock ($0.0001 par value) CLXT The NASDAQ Stock Market LLC (Nasdaq Capital Market) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo ...

Financial Performance - Total revenue for 2022 was $157,000, a significant decrease from $25,987,000 in 2021, representing a decline of approximately 99.4%[267]. - The company recorded stock-based compensation expenses totaling $3,998,000 in 2022, up from $2,090,000 in 2021, indicating an increase of about 91.5%[267]. - Interest expense decreased to $(75,000) in 2022 from $(1,431,000) in 2021, reflecting a reduction of approximately 94.8%[268]. - The company recognized a gain of $1.5 million from the forgiveness of a PPP loan in 2021, which positively impacted its financial position[268]. - As of December 31, 2022, Calyxt had $3.4 million in cash and cash equivalents, with a net loss of $16.9 million for the fiscal year 2022[161]. - Calyxt used $19.4 million in cash for operating activities during the fiscal year ended December 31, 2022[161]. Shareholder and Stock Information - As of June 30, 2022, the aggregate market value of shares of common stock held by non-affiliates was $5,446,012 based on a closing sale price of $0.24[135]. - The number of outstanding shares of common stock on March 1, 2023, was 49,376,160 shares[136]. - As of March 1, 2023, Cellectis holds 48.5% of the outstanding Common Stock, maintaining control over significant operational decisions[249]. - The estimated fair value of Common Warrants as of December 31, 2022, is $0.04, with an expected volatility of 85.0%[261]. - As of December 31, 2022, the company had 7,760,000 common warrants outstanding with an average exercise price of $1.41[280]. Operational Challenges - Calyxt has incurred significant expenses related to the proposed Transactions and may be obligated to pay a termination fee of up to $1.0 million if the merger is not completed[124]. - If the Transactions are not consummated, Calyxt's board may consider liquidation, which would likely result in minimal resources available for distribution to stockholders[125]. - Calyxt has implemented cost reduction measures, including headcount reductions, which may adversely affect its operations and ability to complete the merger[130]. - As of January 31, 2023, Calyxt had 28 full-time employees, with ten in administrative, legal, and finance functions, highlighting potential operational risks due to reduced personnel[132]. - The company faces challenges in securing additional funding and may struggle to find a new strategic partner if the current merger does not proceed[127]. - Calyxt's cost-focused measures may lead to weaknesses in infrastructure and operations, impacting customer acquisition and business development efforts[134]. - The company is focused on three key customer projects, none of which are expected to generate material revenue in the near term[166]. - The company has streamlined its operations to preserve cash sufficient for the merger closing[174]. - Calyxt's ability to continue as a going concern depends on obtaining additional financing if the merger is not completed[164]. Strategic Initiatives - Calyxt's management has focused on scaling production of its Plant Cell Matrix and licensing efforts, indicating a strategic pivot towards core technologies[131]. - The company is pursuing a merger with Cibus, which is expected to close in the second quarter of 2023, subject to various approvals[152]. - If the merger is completed, Cibus equity holders will own a substantial majority of the combined company's common stock, significantly diluting Calyxt's current stockholders[155]. - The Company’s strategy includes licensing its technology, but delays or failures by licensees could harm its financial results[202]. Intellectual Property and Regulatory Risks - The Company may face significant risks related to intellectual property, including inadequate protection of its patents and potential challenges in enforcement[206]. - The Company faces substantial costs and risks in enforcing its intellectual property rights, which may not yield significant commercial advantages[211]. - The uncertainty surrounding patent positions in biotechnology could adversely affect the Company's ability to protect its innovations[212]. - Competitors may exploit the Company's technologies in jurisdictions lacking strong patent protections, potentially undermining its market position[213]. - Changes in patent laws could limit the Company's ability to secure adequate intellectual property protection, impacting its competitive edge[214]. - The Company may face challenges regarding the ownership of intellectual property developed in collaboration with third parties, which could restrict its market potential[215]. - The U.S. government holds certain rights to the Company's government-funded technologies, which could adversely affect its business if exercised[216]. Market and Competitive Environment - The synthetic biology industry is highly competitive, with many competitors having greater resources, which may hinder the Company's market acceptance[185]. - The Company’s ability to attract customers is hampered by capital resource constraints and cost reduction efforts[187]. - The Company’s success in product development is dependent on customer collaborations, which are influenced by its market reputation and technical capabilities[192]. - Market skepticism regarding the viability of the PlantSpring technology platform could adversely affect the Company's ability to raise capital and the value of its common stock[181]. Compliance and Regulatory Environment - The regulatory environment for genetically modified products is uncertain, which could hinder the Company's ability to market its technologies effectively[229]. - The Company is exploring hemp product candidates, but increasing regulations could lead to higher compliance costs[231]. - The Company may face significant challenges in monitoring and controlling the distribution of its products, leading to potential regulatory issues[236]. - The Company is subject to numerous environmental, health, and safety laws, which may incur substantial compliance costs and liabilities[238]. - The regulatory environment in the United States is uncertain and evolving, potentially impacting customer willingness to utilize the Company's products[239]. - The Company anticipates that its customers will bear the costs associated with regulatory activities, which may significantly increase due to changes in regulations[240]. - If the Company fails to comply with Nasdaq's listing requirements, it may face delisting, adversely affecting its financial condition and stock liquidity[255]. Cost Management - Calyxt's management has implemented cost reduction measures, including headcount reductions and renegotiation of service agreements, to manage liquidity[163]. - The Company has suspended non-core activities, including the development of artificial intelligence and machine learning capabilities, to preserve cash[186]. - The Company expects to incur substantial costs in correcting any failures to meet customer specifications, which could adversely affect its business[241]. - Employee benefit plan expenses for the year ended December 31, 2022, were $259,000, a decrease from $274,000 in 2021[266].

Calyxt, Inc. (CLXT) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants William Koschak - CFO Michael Carr - President and CEO Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Calyxt Third Quarter 2022 Financial Results and Corporate Update Conference Call and Webcast. [Operator Instructions] Please also note this conference is being recorded today, November 3, 2022. At this time, I would like to turn the conference over to Bill Koschak, ...